A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients

Population Pharmacokinetics of Bevacizumab in Children with Osteosarcoma: Implications for Dosing

(2014) D. C. Turner et al.   CLINICAL CANCER RESEARCH

Predictive pharmacokinetic–pharmacodynamic modeling of tumor growth after administration of an anti-angiogenic agent, bevacizumab, as single-agent and combination therapy in tumor xenografts

(2013) Maurizio Rocchetti et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Pharmacokinetics, Pharmacodynamics and Physiologically-Based Pharmacokinetic Modelling of Monoclonal Antibodies

(2013) Miroslav Dostalek et al.   CLINICAL PHARMACOKINETICS

Role of bevacizumab in colorectal cancer growth and its adverse effects: A review

(2013) Efstathios T Pavlidis   WORLD JOURNAL OF GASTROENTEROLOGY

Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab

(2012) Nicholas Papadopoulos et al.   ANGIOGENESIS

The Relationship between Drug Clearance and Body Size

(2012) Sarah C. McLeay et al.   CLINICAL PHARMACOKINETICS

Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models

(2011) Martin Bergstrand et al.   AAPS Journal

Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer

(2011) F Loupakis et al.   BRITISH JOURNAL OF CANCER

Gene Expression of Vascular Endothelial Growth Factor A, Thymidylate Synthase, and Tissue Inhibitor of Metalloproteinase 3 in Prediction of Response to Bevacizumab Treatment in Colorectal Cancer Patients

(2011) Toshiaki Watanabe et al.   DISEASES OF THE COLON & RECTUM

Theoretical Considerations of Target-Mediated Drug Disposition Models: Simplifications and Approximations

(2011) Peiming Ma   PHARMACEUTICAL RESEARCH

Increase of Plasma VEGF after Intravenous Administration of Bevacizumab Is Predicted by a Pharmacokinetic Model

(2010) M. O. Stefanini et al.   CANCER RESEARCH

Target-mediated drug disposition model for drugs that bind to more than one target

(2010) Leonid Gibiansky et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Bevacizumab

(2010) F. Kazazi-Hyseni et al.   ONCOLOGIST

An Enzyme-Linked Immunosorbent Assay to Study Bevacizumab Pharmacokinetics

(2010) David Ternant et al.   THERAPEUTIC DRUG MONITORING

Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and Solutions

(2009) Radojka M. Savic et al.   AAPS Journal

Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic–pharmacodynamic modeling of biologics

(2009) Leonid Gibiansky et al.   Expert Opinion on Drug Metabolism & Toxicology

Clinical pharmacokinetics of bevacizumab in patients with solid tumors

(2008) Jian-Feng Lu et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Vascular Endothelial Growth Factor Gene Polymorphisms Associated with Prognosis for Patients with Colorectal Cancer

(2008) J. G. Kim et al.   CLINICAL CANCER RESEARCH

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Approximations of the target-mediated drug disposition model and identifiability of model parameters

(2008) Leonid Gibiansky et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS